Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial

Journal:

The Lancet Oncology

Published:

2025-12-24

DOI:

10.1016/s1470-2045(25)00612-6

Affiliations:

31

Authors:

30

Go to article

Institutions	Authors	Share
Leiden University Medical Center (LUMC), Netherlands	9.000000	0.30
University Medical Center Groningen (UMCG), RUG, Netherlands	2.000000	0.07
Erasmus MC Cancer Institute, Netherlands	2.000000	0.07
Catharina Hospital, Netherlands	1.500000	0.05
University Hospital Tübingen (UKT), Uni Tübingen, Germany	1.500000	0.05
Medical Center Haaglanden (MCH), Netherlands	1.000000	0.03
Radiotherapeutisch Instituut Friesland, Netherlands	1.000000	0.03
Netherlands Comprehensive Cancer Organisation (IKNL), Netherlands	1.000000	0.03
Ghent University Hospital, Belgium	1.000000	0.03
Netherlands Cancer Institute (NKI), Netherlands	1.000000	0.03
Instituut Verbeeten - Tilburg, Netherlands	1.000000	0.03
Radiotherapiegroep, Netherlands	1.000000	0.03
University Medical Center Utrecht (UMC Utrecht), Netherlands	1.000000	0.03
MAASTRO Clinic, Netherlands	1.000000	0.03
Red Cross Hospital Munich gGmbH, Germany	1.000000	0.03
St. Luke's Hospital, Ireland	1.000000	0.03
Institute Gustave-Roussy (IGR), France	1.000000	0.03
General University Hospital in Prague, Czech Republic	0.500000	0.02
Charles University (CU), Czech Republic	0.500000	0.02
Amsterdam UMC, Location AMC, Netherlands	0.500000	0.02
Diakonie-Klinikum Schwäbisch Hall gGmbH, Germany	0.500000	0.02

Interested in Oncology and Carcinogenesis?